FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease ...
--Advisory committee supports surrogate endpoint of sputum culture conversion-- --ALIS currently under FDA Priority Review; PDUFA action date set for September 28, 2018-- BRIDGEWATER, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM …